| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/12/2002 | CA2743731A1 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 09/12/2002 | CA2445018A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | CA2445004A1 Polypeptides of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2442396A1 Method and formula for anti-tumor and anti-matastatic effect |
| 09/12/2002 | CA2440809A1 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439811A1 Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439644A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439178A1 Template-fixed peptidomimetics with antimicrobial activity |
| 09/12/2002 | CA2438829A1 Methods for preparing new taxoids and pharmaceutical compositions containing them |
| 09/12/2002 | CA2438505A1 Altered peptide ligands |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2435277A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | CA2434601A1 Methods for specifically inhibiting histone deacetylase-4 |
| 09/12/2002 | CA2434184A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1239036A1 Polynucleotides, polypeptides, remedies for cancer and vaccines |
| 09/11/2002 | EP1239034A2 Large circular target-specific antisense nucleic acids |
| 09/11/2002 | EP1239033A1 Semaphorin receptor |
| 09/11/2002 | EP1238986A2 Use of Vascular endothelial cell growth factor antagonists |
| 09/11/2002 | EP1238985A1 Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3 |
| 09/11/2002 | EP1238974A1 Heterocycle derivatives and drugs |
| 09/11/2002 | EP1238678A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/11/2002 | EP1238674A2 Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF |
| 09/11/2002 | EP1238666A2 Use of xanthenone-4-acetic acid in the manufacture of a medicament in the treatment of hyperproliferative disorders |
| 09/11/2002 | EP1238282A2 Methods of diagnosis and treatment by binding p75/airm1 |
| 09/11/2002 | EP1238281A2 Cancer associated antigens and uses therefor |
| 09/11/2002 | EP1238098A2 Plasminogen activator assay involving an elastase inhibitor |
| 09/11/2002 | EP1238095A2 Compositions and methods for caspase-induced apoptosis |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238080A2 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238070A2 Therapeutically useful synthetic oligonucleotides |
| 09/11/2002 | EP1238063A2 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 09/11/2002 | EP1238016A1 Substituted phthalocyanines and their precursors |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237916A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 09/11/2002 | EP1237915A2 Polynucleotid encoding the rg1 polypeptide |
| 09/11/2002 | EP1237914A1 Methods for improving secondary metabolite production in fungi |
| 09/11/2002 | EP1237910A2 Trp-protein-related mtr1 protein and dna sequence coding therefor |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237900A1 Subunit optimized fusion proteins |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237888A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/11/2002 | EP1237880A2 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 09/11/2002 | EP1237877A2 Carboxamide-substituted benzimidazol derivatives, methods for the production thereof and their use as medicaments |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237584A1 Receptor binding conjugates |
| 09/11/2002 | EP1237576A1 Antiviral agent for use in treatment of cancer |
| 09/11/2002 | EP1237573A1 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's |
| 09/11/2002 | EP1237567A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237564A1 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 09/11/2002 | EP1237562A2 Dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 09/11/2002 | EP1237558A1 Novel helicobacter pylori-binding substances and use thereof |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1237545A2 Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer |
| 09/11/2002 | EP1237544A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 09/11/2002 | EP1237408A2 Pour-on formulations |
| 09/11/2002 | EP1079838B1 Edelfosin for the treatment of brain tumours |
| 09/11/2002 | EP1017406B1 Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same |
| 09/11/2002 | EP1001811B1 Nanoscale particles having an iron oxide-containing core enveloped by at least two shells |
| 09/11/2002 | EP0956002A4 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(ii) complexes |
| 09/11/2002 | EP0934309B1 New pyridyl alkane acid amides as cytostatics and immunosuppressives |
| 09/11/2002 | EP0880363B1 Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor |
| 09/11/2002 | EP0871467B1 Formulation for peptide release |
| 09/11/2002 | EP0837848B1 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridines having neurotrophic and neuroprotective activity |
| 09/11/2002 | EP0809493B1 A method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds |
| 09/11/2002 | EP0808169A4 Programmed cell death genes and proteins |
| 09/11/2002 | EP0768084B1 Cancerous metastasis inhibitor |
| 09/11/2002 | EP0699070B1 Aurintricarboxylic acid fractions and analogues with anti-angiogenic activity and methods of use |
| 09/11/2002 | CN1369015A Recombinant anti-CD 40 antibody and uses thereof |
| 09/11/2002 | CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties |
| 09/11/2002 | CN1368973A Novel xanthone compounds, their preparation and use as medicament |
| 09/11/2002 | CN1368970A Substituted 1,4-dihydroindeno [1,2-C] pyrazoles as inhibitors of tyrosine kinase |
| 09/11/2002 | CN1368963A Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/11/2002 | CN1368962A Fluorene derivatives |
| 09/11/2002 | CN1368958A Arylsulfonamido-substituted hydroxamic acid derivatives |
| 09/11/2002 | CN1368892A Sustained release formulation of peptide |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368884A Method for modulating FXR receptor activity |
| 09/11/2002 | CN1368880A Water-miscible pharmaceutical compositions of paclitaxel |
| 09/11/2002 | CN1368874A Implantable active ingredient depot |
| 09/11/2002 | CN1368853A Prophylactic dietary supplement based on milk |